Divalproex Sodium Capsule, Delayed Release
Product Images NDC 0904-6615

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0904-6615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A cumulative distribution plot comparing percentage reduction in CPS rate between Divalproex Sodium and placebo groups. The x-axis represents the percentage of patients, and the y-axis shows the percentage reduction in CPS rate from -100% to 100%, with annotations indicating worsening below zero and improvement above zero. The solid line represents Divalproex Sodium, and the dashed line represents placebo.*

FDA Label Image

Figure2 (Figure2)

A line graph showing percentage reduction in CPS rate versus percentage of patients, comparing high dose and low dose treatments. The vertical axis measures improvement or worsening in CPS rate, with a horizontal baseline at no change. The horizontal axis shows the percentage of patients from 100 to 0.*

FDA Label Image

Carton Label (Image 01)

Divalproex sodium 125 mg delayed-release capsules, USP (sprinkle) in unit dose packaging by Major Pharmaceuticals. The label displays the product name, active ingredient with valproic acid activity, and dosing strength. It includes instructions for pharmacist dispensing with medication guide, prescription-only designation, and packaging quantity of 100 capsules. Storage and handling details, manufacturer and distributor information are also present.*

FDA Label Image

Picture1 (Picture1)

Divalproex sodium delayed-release capsule, 125 mg, shown in the image. The capsule is primarily white with a dark colored cap and partial visible printed text. The product is labeled by Major Pharmaceuticals for oral human prescription use.*

FDA Label Image

Picture2 (Picture2)

Divalproex sodium 125 mg delayed-release oral capsule. The image shows a close-up of the capsule's imprint, featuring black text on a white background, partially visible as 'DVAL'. The product is manufactured by Major Pharmaceuticals and marked with NDC 0904-6615.*

FDA Label Image

Picture3 (Picture3)

Divalproex sodium 125 mg delayed-release oral capsule by Major Pharmaceuticals. The grayscale image shows a capsule with visible small beads inside spilling out, illustrating the delayed-release formulation.*

FDA Label Image

Picture4 (Picture4)

An illustration showing a young child drinking liquid medicine from a measuring spoon or small cup. The image visually demonstrates oral administration of a liquid medication dose.*

FDA Label Image

Structure (Structure)

Chemical structure of divalproex sodium showing its molecular components including sodium ion, carboxyl groups, and hydrocarbon chains arranged in a repeating polymeric form represented by the variable n.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.